gradient color.

News & Events

  • Press Release

Lumina Pharmaceuticals announces FDA clearance of IND application for CM500

Novel, first-in-class radiopharmaceutical targeting a hallmark of the solid tumor microenvironment December 22, 2025, Boston, MA – Lumina Pharmaceuticals, a clinical-stage radiopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)

  • Press Release

Lumina Pharmaceuticals Announces Hire of Eric Hoffman as Chief Business Officer

December 1, 2025: Lumina Pharmaceuticals, a clinical stage company developing radiopharmaceuticals, announced today that industry expert Eric S. Hoffman, Ph.D., will join the company as Chief Business Officer. In this role, Dr. Hoffman

  • Press Release

Science Translational Medicine Publishes Article Outlining Development of a Fibrin-Targeted Theranostic for Gastric Cancer

In the publication, the authors describe a theranostic approach for targeting fibrin deposition in the tumor extracellular matrix first with a copper-64 labeled, fibrin-specific positron emission tomography (PET) imaging probe and then with
  • Press Release

Lumina Pharmaceuticals Awarded $2 million SBIR Phase II Fast Track NIH Grant to Support the Development of Novel Therapeutics to Solid Tumor Cancer

The Fast Track award from NCI represents another important milestone for Lumina as we continue to advance our platform of targeted molecular probes for medical imaging and radioligand therapy,
Partnerships in Imaging and Innovation

Connect With Us

Let’s Connect
gradient color.
Close